Access detailed search options for content from the Clinical Journal of Oncology Nursing & Oncology Nursing Forum below.
This module explores unique professional issues that accompany advanced oncology nursing practice. Explore topics including APRN education, accreditation, licensure, and certification standards, as well as professional roles and state practice acts.
Gain a basic understanding of the legislative process and health policy advocacy so that you can make sure the voice of oncology nurses is heard loud and clear. This free self-directed, self-paced course demonstrates how, in a short period of time, you can influence critical policy-making decisions.
The Fundamentals of Chemotherapy Immunotherapy Administration Renewal Course builds on the lessons you received in the Fundamentals of Chemotherapy Immunotherapy Administration Course to ensure that your chemotherapy and immunotherapy knowledge remains current and you’re continuing to progress as an experienced oncology RN.
More than 40% of adult patients with mismatch repair deficient (dMMR) recurrent or advanced endometrial cancer had an overall response receiving dostarlimab-gxly (Jemperli), and more than 90% of those lasted six months or longer during the drug’s clinical trials. Those results led the U.S. Food and Drug Administration (FDA) to grant the agent its original accelerated approval in 2021 for the indication. FDA expanded the accelerated approval later that year to include all recurrent or advanced solid tumors with dMMR demonstrated through an FDA-approved diagnostic test.
This position statement was endorsed by the ONS Board in September 2019 and was republished with permission from the American Nurses Association (ANA).
Prepare for your AOCNP® certification exam with the AOCNP® Certification Review Bundle. This bundle offers access to seven online courses and the latest edition of the Advanced Oncology Nursing Certification Review and Resource Manual.
The ONS/ONCC Chemotherapy Immunotherapy Certificate Renewal Course will guide you through four strategically planned case studies to ensure that your chemotherapy and immunotherapy knowledge stays current and you’re continuing to progress as an experienced oncology RN.
In July 2020, the U.S. Food and Drug Administration approved decitabine and cedazuridine (Inqovi®) tablets for the treatment of adults with myelodysplastic syndromes (MDS).